Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Carcinoma, Renal Cell Clinical Trial

Official title:

A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00445042
• Other study ID #: PAC IRB#03-0194-05
• Secondary ID: Sorafenib-RCC-01
• Status: Completed
• Phase: Phase 2
• First received: March 7, 2007
• Last updated: March 15, 2016
• Start date: November 2005
• Est. completion date: October 2008

Study information

• Verified date: March 2016
• Source: The Methodist Hospital System
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and toxicity levels of Dose Escalated Sorafenib in the treatment of patients with renal cancer.

Description:

Because tumors may have multiple mechanisms to induce angiogenesis, blockade with sorafenib may demonstrate efficacy. Doses of sorafenib (400 mg b.i.d.) as a single agent is with minimal toxicity, presents an opportunity to explore a more intensive drug administration. This study will allow individual patient titration (e,g,, intrapatient dose escalation) as per protocol.

This provides the basis for the dose escalation development of sorafenib. The study is designed to evaluate the ability for patients to dose escalate. Secondary endpoints include; response, time to progression, and overall survival in patients with MRCC. Tissue correlation to evaluate the impact of expression of receptor on clinical outcome will be retrospectively performed. Laboratory correlation of plasma VEGF levels will be correlated and evaluated to clinical outcome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: October 2008
• Est. primary completion date: September 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytological confirmed metastatic or unresectable clear cell renal cell carcinoma.

• No more than one prior systemic therapy. No prior vascular endothelial growth factor receptor agents.

• Patients with primary tumor in place are strongly encouraged to undergo nephrectomy prior to initiation of study agent.

• Prior palliative radiotherapy to metastatic lesion(s) is permitted.

• All major surgery of any type and/or radiotherapy must be completed at least 4 weeks prior to registration.

• Patients must have metastatic or unresectable disease.

• Paraffin RCC tissue blocks or unstained slides must be available.

• Karnofsky performance status > 70 % .

• Not pregnant

• Age > 18

• Must meet required initial laboratory values

Exclusion Criteria:

• No ongoing hemoptysis, or cerebrovascular accident within 12 months, or peripheral vascular disease with claudication on less than 1 block, or history of clinically significant bleeding.

• No deep vein thrombosis or pulmonary embolus within one year of study enrollment and no ongoing need for full-dose oral or parenteral anticoagulation. Low dose coumadin (1 mg) for maintenance of catheter patency or daily prophylactic aspirin is allowed.

• No evidence of current central nervous system (CNS) metastasis. All patients must undergo an MRI or CT scan of the brain (with contrast, if possible) within 42 days prior to registration. Any imaging abnormality indicative of CNS metastases will exclude the patient from the study.

• No significant cardiovascular disease defined as congestive heart failure (New York Heart Association Class II, II or IV) angina pectoris requiring nitrate therapy, or recent myocardial infarction (within the last 6 months).

• No patients with uncontrolled hypertension (defined as blood pressure of >160 mmHg systolic and/or > 90 mmHg diastolic on medication).

• Any ongoing requirement for systemic corticosteroid therapy is not permitted. Topical and/or inhaled steroids are allowed.

• No pre-existing thyroid abnormality whose thyroid function cannot be maintained in the normal range by medication are ineligible.

• No uncontrolled psychiatric disorder.

• Patients with delayed healing of wounds, ulcers and/or bone fractures are not eligible

• Patients with a 'currently active' second malignancy other than non-melanoma skin cancers are not eligible. Patients are not considered to have a 'currently active' malignancy if they have completed anti-cancer therapy and are considered by their physician to be a less than 30% risk of relapse.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell

Intervention

Drug:
• Sorafenib
The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.

Locations

Country	Name	City	State
United States	Methodist Hospital - Baylor College of Medicine	Houston	Texas

Sponsors (3)

Lead Sponsor	Collaborator
The Methodist Hospital System	Bayer, Onyx Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor progression rate by RECIST criteria		restaging every 8 weeks	No
Secondary	Overall response rate		restaging every 8 weeks	No
Secondary	Time to progression and overall survival		restaging every 8 weeks	No

External Links

•   Click here for more information about this study